Nakano S, Kihara Y, Otsuki M
Third Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
Pancreas. 1998 Mar;16(2):169-75. doi: 10.1097/00006676-199803000-00011.
We examined the effects of treatment with cholecystokinin (CCK) octapeptide (CCK-8) and the CCK receptor antagonist loxiglumide on the recovery of exocrine pancreas in post-acute pancreatitic rats. Acute pancreatitis was induced in rats by intravenous infusion of 20 microg/kg/h cerulein for 4 h. At 24 h after the start of cerulein infusion, rats were divided into nine treatment groups: oral administration of saline (control), or oral administration of 10 or 50 mg/kg body weight loxiglumide twice daily for the first 3 days, followed by saline administration (Loxi-1 and Loxi-2), 10 or 50 mg/kg body weight loxiglumide twice daily for 6 days (Loxi-3 and Loxi-4), oral administration of saline or 10 or 50 mg/kg body weight loxiglumide twice daily for the first 3 days, followed by subcutaneous injection of 2.5 microg/kg body weight CCK-8 twice daily for the next 3 days (CCK-1, CCK-2, and CCK-3), and subcutaneous injection of 2.5 microg/kg body weight CCK-8 twice daily for 6 days (CCK-4). Pancreatic wet weight and biochemical changes were evaluated on day 8 at 12 h after the last treatment. Treatment with loxiglumide (Loxi-3 and Loxi-4) or CCK-8 for 6 days (CCK-4) or with a high dose of loxiglumide for the first 3 days (Loxi-2) significantly suppressed the recovery of pancreatic weight and DNA content compared to saline treatment or to the untreated normal control rats. However, when loxiglumide treatment was followed by 3 days of CCK-8 injections (CCK-2 and CCK-3), pancreatic protein and DNA content recovered to levels comparable to or above the control levels. The most remarkable increase in enzyme content was obtained in postpancreatitic rats treated with high-dose loxiglumide for the first 3 days, followed by CCK-8 injection (CCK-3). On the other hand, 6 days of CCK-8 treatment (CCK-4) had no significant influences on pancreatic enzyme contents. These results suggest that the most favorable strategy for the treatment of acute pancreatitis is to give high-dose loxiglumide during the early stage for only a short period, followed by CCK-8 administration.
我们研究了用胆囊收缩素(CCK)八肽(CCK-8)和CCK受体拮抗剂洛西肽胺治疗对急性胰腺炎后大鼠外分泌胰腺恢复的影响。通过静脉输注20微克/千克/小时的雨蛙素4小时诱导大鼠发生急性胰腺炎。在开始输注雨蛙素24小时后,将大鼠分为九个治疗组:口服生理盐水(对照组),或在最初3天每天两次口服10或50毫克/千克体重的洛西肽胺,随后给予生理盐水(Loxi-1和Loxi-2),每天两次口服10或50毫克/千克体重的洛西肽胺,共6天(Loxi-3和Loxi-4),在最初3天每天两次口服生理盐水或10或50毫克/千克体重的洛西肽胺,随后在接下来3天每天两次皮下注射2.5微克/千克体重的CCK-8(CCK-1、CCK-2和CCK-3),以及每天两次皮下注射2.5微克/千克体重的CCK-8,共6天(CCK-4)。在最后一次治疗后12小时的第8天评估胰腺湿重和生化变化。与生理盐水治疗或未治疗的正常对照大鼠相比,用洛西肽胺(Loxi-3和Loxi-4)或CCK-8治疗6天(CCK-4)或在最初3天用高剂量洛西肽胺治疗(Loxi-2)显著抑制了胰腺重量和DNA含量的恢复。然而,当洛西肽胺治疗后接着注射3天的CCK-8(CCK-2和CCK-3)时,胰腺蛋白质和DNA含量恢复到与对照水平相当或高于对照水平。在用高剂量洛西肽胺在最初3天治疗,随后注射CCK-8(CCK-3)的胰腺炎后大鼠中,酶含量增加最为显著。另一方面,6天的CCK-8治疗(CCK-4)对胰腺酶含量没有显著影响。这些结果表明,治疗急性胰腺炎最有利的策略是在早期仅短时间给予高剂量洛西肽胺,随后给予CCK-8。